Page 3 - Nyse Ebs News Today

Emergent BioSolutions (NYSE:EBS – Get Rating) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. The business had revenue of $165.10 million during the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative net […]

Emergent BioSolutions (NYSE:EBS – Get Rating) released its earnings results on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. The business had revenue of $165.10 million during the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative net margin […]

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 7,190,000 shares, a decline of 5.4% from the March 31st total of 7,600,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is […]

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have been assigned an average recommendation of “Hold” from the eight brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. […]

Emergent BioSolutions (NYSE:EBS – Get Rating) is set to issue its quarterly earnings data after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($1.67) per share for the quarter. Emergent BioSolutions has set its FY 2023 guidance at EPS.Parties that wish to register for the company’s conference call […]

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have received a consensus recommendation of “Hold” from the eight research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. […]

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 7,600,000 shares, an increase of 22.4% from the March 15th total of 6,210,000 shares. Approximately 18.7% of the company’s shares are sold short. Based on an average […]

Benchmark upgraded shares of Emergent BioSolutions (NYSE:EBS – Get Rating) from a hold rating to a buy rating in a report released on Monday morning, The Fly reports. Benchmark currently has $22.00 price target on the biopharmaceutical company’s stock. EBS has been the subject of a number of other research reports. TheStreet lowered Emergent BioSolutions […]

Benchmark upgraded shares of Emergent BioSolutions (NYSE:EBS – Get Rating) from a hold rating to a buy rating in a report released on Monday, The Fly reports. Benchmark currently has $22.00 target price on the biopharmaceutical company’s stock. Several other analysts have also weighed in on EBS. TheStreet lowered Emergent BioSolutions from a c- rating […]

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $14.00, but opened at $13.27. Emergent BioSolutions shares last traded at $12.15, with a volume of 395,192 shares traded. The biopharmaceutical company reported ($0.31) earnings […]